NCT05970224View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

August 31, 2025

Study Completion Date

July 31, 2027

Conditions
Intracerebral Hemorrhage
Interventions
DRUG

Ir-CPI

Participants receive a single intravenous dose of Ir-CPI during 48 hours

Trial Locations (10)

1070

HUB Erasme, Brussels

7000

CHU Ambroise Paré, Mons

8000

AZ Sint-Jan, Bruges

8400

AZ Damiaan, Ostend

8500

AZ Groeninge, Kortrijk

9000

UZ Gent, Ghent

Unknown

UCL St Luc, Brussels

UZ Brussel, Brussels

UZ Leuven, Leuven

Clinique CHC MontLégia, Liège

Sponsors

Lead Sponsor

Bioxodes S.A.
All Listed Sponsors
lead

Bioxodes S.A.

INDUSTRY

NCT05970224 - A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage | Biotech Hunter | Biotech Hunter